424
R. Bach et al.
LETTER
Soc. 1994, 116, 405. (e) Anderson, D. R.; Faibish, N. C.;
Beak, P. J. Am. Chem. Soc. 1999, 121, 7553. (f) Meigh,
J.-P.; Álvarez, M.; Joule, J. A. J. Chem. Soc., Perkin Trans.
1 2001, 2012. (g) Llopart, C. C.; Ferrer, C.; Joule, J. A. Can.
J. Chem. 2004, 82, 1649.
twice with EtOAc, the organic phases were combined, washed with
brine, dried over MgSO4, and the solvent was removed under re-
duced pressure. The crude product was purified by flash chromatog-
raphy (SiO2; PE–EtOAc, 1:1) to give the title compound (89 mg,
0.30 mmol, 81%) as a colourless oil.
(6) 2-Phenylpyrrolidine was made in enantiomerically enriched
form (er = 92:8 by GC) by the method of: Verdaguer, X.;
Lange, U.; Reding, M. T.; Buchwald, S. L. J. Am. Chem.
Soc. 1996, 118, 6784.
(7) DMPU promotes reactions involving dearomatising addition
of organolithiums to aromatic rings. See: (a) Clayden, J.;
Knowles, F. E.; Menet, C. J. Synlett 2003, 1701.
Rf = 0.70 (EtOAc). IR (CHCl3): nmax = 3353 (NH), 1636 (C=O),
1522 cm–1. 1H NMR (400 MHz, DMSO-d6): d = 7.31–7.25 (m, 2 H),
7.21–7.12 (m, 3 H), 7.10–7.06 (m, 2 H), 7.04–6.98 (m, 1 H), 6.67
(d, 1 H, J = 7.8 Hz), 6.18 (br q, 1 H, J = 4.4 Hz), 3.31–3.22 (m, 1
H), 2.84–2.77 (m, 2 H), 2.56 (s, 3 H), 2.52 (d, 3 H, J = 4.4 Hz),
2.19–2.11 (m, 1 H), 1.77–1.66 (m, 1 H), 1.63–1.52 (m, 1 H). 13C
NMR (100 MHz, DMSO-d6): d = 158.7, 146.3, 141.6, 137.3, 129.0,
128.8, 127.6, 127.1, 126.8, 125.9, 125.1, 66.8, 35.8, 35.6, 28.0,
27.1, 18.1. MS (ES+): m/z = 317 [M + Na+], 295 [MH+], 207, 177.
HRMS (ES+): m/z calcd for C19H23N2O [MH+]: 295.1805; found:
295.1804.
(b) Clayden, J.; Parris, S.; Cabedo, N.; Payne, A. H. Angew.
Chem. Int. Ed. 2008, 47, 5060.
(8) Alongside remaining starting material, byproducts from this
reaction included those arising from ortholithiation of the
aryl ring followed by anionic ortho-Fries rearrangement (see
Sibi, M. P.; Snieckus, V. J. Org. Chem. 1983, 48, 1935).
Quenching the reaction mixture with TMSCl yielded no
products of silylation a to nitrogen.
(9) For recent synthesis of pyrrolidines containing quaternary
centres, see: (a) Calaza, M. I.; Cativiela, C. Eur. J. Org.
Chem. 2008, 3427. (b) Makosza, M.; Sulikowski, D.;
Maltsev, O. Synlett 2008, 1711.
(1-Phenyl-2,3,4-trihydronaphthalen-1-yl)methylamine (21a)
Urea 20a (42 mg, 0.14 mmol) was dissolved in n-BuOH and heated
under reflux (118 °C) for 2 d. The solvent was removed, and the
crude product was purified by flash chromatography (SiO2; PE–
EtOAc, 2:1) to give the title compound (24 mg, 0.10 mmol, 71%) as
a colourless oil.
Rf = 0.26 (PE–EtOAc, 1:1). IR (CHCl3): nmax = 3338 (w, NH), 2937,
756, 702 cm–1. 1H NMR (400 MHz, CDCl3): d = 7.27–7.12 (m, 8 H),
7.05–7.01 (m, 1 H), 2.87–2.81 (m, 2 H), 2.28–2.21 (m, 1 H), 2.27
(s, 3 H), 2.02–1.94 (m, 1 H), 1.87 (br s, 1 H), 1.85–1.75 (m, 1 H),
1.70–1.58 (m, 1 H). 13C NMR (100 MHz, CDCl3): d = 149.5, 139.9,
139.0, 129.0, 128.7, 127.7, 127.7, 126.4, 126.3, 125.6, 63.0, 36.0,
30.0, 29.9, 19.5. MS (ES+): m/z = 238 [MH+], 227, 207. HRMS
(ES+): m/z calcd for C17H20N [MH+]: 238.1590; found: 238.1595.
(10) The X-ray crystallographic data for 9d has been deposited
with the Cambridge Crystallographic Database, deposition
number 706267.
(11) For a review of the chemistry of nicotine analogues, see:
(a) Wagner, F.; Comins, D. L. Tetrahedron 2007, 63, 8065.
Conformationally constrained analogues of nicotine are of
medicinal interest, see: (b) Papke, R. L.; Zheng, G.;
Horenstein, N. A.; Dwoskin, L. P.; Crooks, P. A. Bioorg.
Med. Chem. Lett. 2005, 15, 3874. (c) Luo, S.; Fang, F.;
Zhao, M.; Zhai, H. Tetrahedron 2004, 60, 5353. (d) Rao,
T. S.; Sacaan, A. I.; Menzaghi, F. M.; Reid, R. T.; Adams,
P. B.; Correa, L. D.; Whelan, K. T.; Vernier, J.-M. Brain
Res. 2004, 1003, 4. (e) Sarkar, T. K.; Basak, S.; Wainer, I.;
Moaddel, R.; Yamaguchi, R.; Jozwiak, K.; Chen, H.-T.; Lin,
C.-C. J. Med. Chem. 2004, 47, 6691. (f) Denton, T. T.;
Zhang, Xi.; Cashman, J. R. J. Med. Chem. 2005, 48, 224.
(g) Sarkar, T. K.; Basak, S.; Slanina, Z.; Chow, T. J. J. Org.
Chem. 2003, 68, 4206. (h) Zhai, H.; Liu, P.; Luo, S.; Fang,
F.; Zhao, M. Org. Lett. 2002, 4, 4385. (i) Ullrich, T.; Krich,
S.; Binder, D.; Mereiter, K.; Anderson, D. J.; Meyer, M. D.;
Pyerin, M. J. Med. Chem. 2002, 45, 4047. (j) Xu, R.;
Dwoskin, L. P.; Grinevich, V.; Sumithran, S. P.; Crooks,
P. A. Drug Dev. Res. 2002, 55, 173. (k) Ullrich, T.; Binder,
D.; Pyerin, M. Tetrahedron Lett. 2002, 43, 177. (l) Ferretti,
G.; Dukat, M.; Giannella, M.; Piergentili, A.; Pigini, M.;
Quaglia, W.; Damaj, M. I.; Martin, B. R.; Glennon, R. A.
Bioorg. Med. Chem. Lett. 2000, 10, 2665. (m) Kim, K. H.;
Lin, N.-H.; Anderson, D. J. Bioorg. Med. Chem. 1996, 4,
2211. (n) Glennon, R. A.; Maarouf, A.; Fahmy, S.; Martin,
B.; Fang, F.; Yousif, M.; Shafik, R. M.; Dukat, M. Med.
Chem. Res. 1993, 2, 546. (o) Meyers, A. I.; Marra, J. M.
Tetrahedron Lett. 1985, 26, 5863.
Acknowledgment
We are grateful to the Deutscher Akademischer Austauschdienst for
a postdoctoral fellowship (to UH), and to the Leverhulme Trust and
the Erasmus programme of the EU for support. We acknowledge
the contribution of Dr. Damian Grainger for the synthesis and rear-
rangement of 15.
References and Notes
(1) (a) Clayden, J. Organolithiums: Selectivity for Synthesis;
Pergamon: Oxford, 2002. (b) Gawley, R. E.; Coldham, I. In
The Chemistry of Organolithium Compounds; Rappoport,
Z.; Marek, I., Eds.; Wiley: New York, 2004, 997–1053.
(c) Beak, P.; Johnson, T. A.; Kim, D. S.; Lim, S. H. Top.
Organomet. Chem. 2003, 5, 139.
(2) (a) Campos, K. R. Chem. Soc. Rev. 2007, 36, 1027.
(b) O’Brien, P.; Bilke, J. L. Angew. Chem. Int. Ed. 2008, 47,
2734.
(3) (a) Clayden, J.; Dufour, J.; Grainger, D.; Helliwell, M.
J. Am. Chem. Soc. 2007, 129, 7488. (b) Clayden, J.;
Hennecke, U. Org. Lett. 2008, 10, 3567.
(4) (a) Kerrick, S. T.; Beak, P. J. Am. Chem. Soc. 1991, 113,
9708. (b) Beak, P.; Kerrick, S. T.; Wu, S.; Chu, J. J. Am.
Chem. Soc. 1994, 116, 3231.
(12) In THF, decomposition products suggest that lithiation is
followed by intra- and/or intermolecular addition to the 2- or
4-position of the pyridyl ring, rather than the 3-position.
(13) Compound 19e was made by standard methods from
commercially available material.
(5) (a) Clayden, J.; Dufour, J. Tetrahedron Lett. 2006, 47, 6945.
(b) Clayden, J.; Turner, H.; Pickworth, M.; Adler, T. Org.
Lett. 2005, 7, 3147. (c) Hassel, T.; Seebach, D. Helv. Chim.
Acta 1978, 61, 2237. (d) Resek, J. E.; Beak, P. J. Am. Chem.
Synlett 2009, No. 3, 421–424 © Thieme Stuttgart · New York